# A Phase IIb, single arm, multicenter trial of sacituzumab govitecan in Chinese patients with metastatic triple-negative breast cancer who received at least two prior treatments

Source: https://onco.cc/key-papers/paper-nct04454437-int-j-cancer-2023/  
OnCo record `paper-nct04454437-int-j-cancer-2023` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Published report from the trial registered as NCT04454437, in International journal of cancer (2023), chosen as the most cited paper whose own text cites the registry id.

## Summary

Refractory or relapsing metastatic triple-negative breast cancer (mTNBC) has a poor prognosis. Sacituzumab govitecan (SG) is a novel antibody-drug conjugate, targeting human trophoblast cell-surface antigen 2 (Trop-2). This is the first report of SG's efficacy and safety in Chinese patients with mTNBC. EVER-132-001 (NCT04454437) was a multicenter, single-arm, Phase IIb study in Chinese patients with mTNBC who failed ≥2 prior chemotherapy regimens. Eligible patients received 10 mg/kg SG on Days 1 and 8 of each 21-day treatment cycle, until disease progression/unacceptable toxicity. The primary endpoint was objective response rate (ORR) assessed by the Independent Review Committee. Secondary endpoints included: duration of response (DOR), clinical benefit rate (CBR), progression-free survival (PFS), overall survival (OS) and safety. Eighty female Chinese patients (median age 47.6 years; range 24-69.9 years) received ≥1 SG dose with a median of 8 treatment cycles by the cutoff date (August 6, 2021). Median number of prior systemic cancer treatments was 4.0 (range 2.0-8.0). ORR and CBR were reported 38.8% (95% confidence interval [CI]: 28.06-50.30) and 43.8% (95% CI, 32.68-55.30) of patients, respectively. The median PFS was 5.55 months (95% CI, 4.14-N/A). SG-related Grade ≥3 treatment-emergent adverse events (TEAEs) were reported in 71.3%, the most common were neutrophil count decreased (62.5%), white blood cell count decreased (48.8%) and anemia (21.3%); 6.3% discontinued SG because of TEAEs. SG demonstrated substantial clinical activity in heavily pretreated Chinese patients with mTNBC. The observed safety profile was generally manageable.

Indexed on Europe PMC as PubMed record 36621000 (DOI 10.1002/ijc.34424). Its abstract cites the registry id NCT04454437, which is how it was matched to this trial; no figure has been checked by an editor.

## Fields

- Kind: Key paper
- Last checked: 2026-09-22
- Tags: europepmc-ingest
- Journal: International journal of cancer
- Year: 2023
- DOI: 10.1002/ijc.34424
- Authors: Xu B, Ma F, Wang T, et al.
- What it means: This is the paper Europe PMC returns for registry id NCT04454437 with the most citations, so it is the natural first reading for anyone following the trial. Read the abstract above alongside the trial page and the registry entry; the record was linked automatically and its figures have not been checked by hand.
- Caveats: Matched to the trial by the registry id cited in the Europe PMC record; the summary reproduces the record's abstract and no figure has been verified against the full paper.

## Sources

- Int J Cancer 2023: https://doi.org/10.1002/ijc.34424
- PubMed: https://pubmed.ncbi.nlm.nih.gov/36621000/
- Europe PMC: https://europepmc.org/article/MED/36621000
- ClinicalTrials.gov NCT04454437: https://clinicaltrials.gov/study/NCT04454437

## Connected records

- trials: [Study of Sacituzumab Govitecan in Chinese Patients With Metastatic Triple-negative Breast Cancer Who Received at Least Two Prior Treatments](https://onco.cc/trials/nct04454437/)
- journals: [International journal of cancer](https://onco.cc/journals/international-journal-of-cancer/)

---
JSON: https://onco.cc/api/v1/entities/paper-nct04454437-int-j-cancer-2023.json